

April 7, 2023
IWAKI SEIYAKU CO., LTD.

Phase 2 Clinical Trial Initiated for Verrucae Vulgaris (Common Warts) Caused by Human Papillomavirus Infection

IWAKI SEIYAKU CO., LTD. (IWAKI SEIYAKU) announces that IWAKI SEIYAKU and KinoPharma, Inc. (KinoPharma) have started a Phase 2 clinical trial for the indication for treatment of verrucae vulgaris using a formulation developed by IWAKI SEIYAKU. The details are as follows.

IWAKI SEIYAKU and KinoPharma have jointly developed the formulation since January 2021. In order to proceed with clinical development for the indication for treatment of verrucae vulgaris based on the results, IWAKI SEIYAKU and KinoPharma entered into a co-development and commercialization agreement in August 2022. After the drug safety using the formulation was confirmed in animal and human testing, it was decided to start a Phase 2 clinical trial to confirm the effectiveness for verrucae vulgaris. Accordingly, KinoPharma submitted a notification of a clinical trial to the Pharmaceuticals and Medical Devices Agency (PMDA) today.

Contact:

IWAKI SEIYAKU CO., LTD.

Corporate Planning Department

E-mail : iyakukaihatsu2011@iwakiseiyaku.co.jp